MindMed Launches Groundbreaking Phase 2a Trial: Low-Dose LSD for Adult ADHD Treatment

MindMed has launched a Phase 2a clinical trial to investigate the potential of low-dose LSD in treating adult attention deficit hyperactivity disorder (ADHD)[1]. The trial, conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands, aims to evaluate the therapeutic benefits of repeated low doses of LSD[1].

The study is led by Dr. Matthias Liechti from the University Hospital Basel and Dr. Kim Kuypers from Maastricht University, both renowned experts in psychedelic research[1]. It will enroll 52 adult patients with ADHD who will receive either 20μg of LSD or a placebo twice a week for six weeks[1].

The primary endpoint of the trial is the change in ADHD symptoms after six weeks, as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS)[1]. This scale assesses 18 items related to inattention, impulsivity, and hyperactivity, with scores ranging from 0 to 54[1].

Robert Barrow, CEO of MindMed, expressed enthusiasm for the trial, citing growing evidence of LSD’s potential to improve mood and cognitive processes[1]. He noted that low doses of LSD have shown to be safe and well-tolerated in previous studies[1].

Dr. Liechti highlighted that while single high doses of psychedelics have demonstrated lasting mood benefits, this trial aims to explore the potential therapeutic effects of very low doses given repeatedly[1].

The study is part of MindMed’s broader strategy to develop psychedelic-inspired therapies for mental health conditions. Adult ADHD affects an estimated 10 million Americans, with only about 10.9% seeking treatment[1]. The U.S. market for ADHD medications is currently valued at $12.9 billion annually[1].

Citations:
[1] https://mindmed.co/news/press-release/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd/
[2] https://cris.maastrichtuniversity.nl/en/clippings/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-a
[3] https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
[4] https://www.newswire.ca/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-884764347.html
[5] https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html